These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12197312)

  • 1. Guiding molecules towards drug-likeness.
    Egan WJ; Walters WP; Murcko MA
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):540-9. PubMed ID: 12197312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead optimization in the nondrug-like space.
    Zhao H
    Drug Discov Today; 2011 Feb; 16(3-4):158-63. PubMed ID: 21147254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing drug-likeness--what are we missing?
    Vistoli G; Pedretti A; Testa B
    Drug Discov Today; 2008 Apr; 13(7-8):285-94. PubMed ID: 18405840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection criteria for drug-like compounds.
    Muegge I
    Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular properties that influence oral drug-like behavior.
    Lajiness MS; Vieth M; Erickson J
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):470-7. PubMed ID: 15338956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular optimization using computational multi-objective methods.
    Nicolaou CA; Brown N; Pattichis CS
    Curr Opin Drug Discov Devel; 2007 May; 10(3):316-24. PubMed ID: 17554858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion.
    Wang J; Krudy G; Xie XQ; Wu C; Holland G
    J Chem Inf Model; 2006; 46(6):2674-83. PubMed ID: 17125207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.
    Dobson PD; Patel Y; Kell DB
    Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design strategies for building drug-like chemical libraries.
    Mitchell T; Showell GA
    Curr Opin Drug Discov Devel; 2001 May; 4(3):314-8. PubMed ID: 11560064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of drugs: advances in determination, prediction and engineering.
    Datta S; Grant DJ
    Nat Rev Drug Discov; 2004 Jan; 3(1):42-57. PubMed ID: 14708020
    [No Abstract]   [Full Text] [Related]  

  • 13. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of flavin-containing monooxygenases in drug metabolism and development.
    Cashman JR
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):486-93. PubMed ID: 12951812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocarriers.
    Torchilin VP
    Pharm Res; 2007 Dec; 24(12):2333-4. PubMed ID: 17934800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.
    Langer T; Krovat EM
    Curr Opin Drug Discov Devel; 2003 May; 6(3):370-6. PubMed ID: 12833670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physics-based methods for studying protein-ligand interactions.
    Huang N; Jacobson MP
    Curr Opin Drug Discov Devel; 2007 May; 10(3):325-31. PubMed ID: 17554859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A screening study of ChirBase molecular database to explore the expanded chiral pool derived from the application of chiral chromatography.
    Piras P; Roussel C
    J Pharm Biomed Anal; 2008 Apr; 46(5):839-47. PubMed ID: 17942261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process optimization using combinatorial design principles: parallel synthesis and design of experiment methods.
    Gooding OW
    Curr Opin Chem Biol; 2004 Jun; 8(3):297-304. PubMed ID: 15183328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.